Envoy Medical Reports Q2 2026 Results, Submits First PMA Module to FDA, and Posts Positive 12-Month Trial Data
COCH sits 94% above its 52-week low of $0.363.
Summary
Envoy Medical reported Q2 2026 results with a $7.3M net loss and $19.7M in cash, submitted the first module of its PMA application to the FDA, and announced positive 12-month data from its pivotal cochlear implant trial.
Key Events · Earnings and Guidance · COCH
-
Q2 2026 Financial Results
Net loss of $7.3 million ($0.07 per share) on minimal revenue of $51,000. R&D expenses rose to $3.1 million, reflecting clinical trial and PMA submission costs. Cash stood at $19.7 million as of June 30, 2026.
-
First PMA Module Submitted to FDA
The company submitted the first of four modules of its modular PMA application for the Acclaim cochlear implant, with the final module targeted for Q2 2027. This initiates FDA review and provides a defined regulatory cadence.
-
Positive 12-Month Trial Data
The first 10 patients in the pivotal trial achieved a mean CNC word recognition score of 53.2% at 12 months, a 38.0 percentage point improvement from baseline, demonstrating continued speech perception gains.
-
Full Trial Cohort Passes Three-Month Follow-Up
All 56 patients in the pivotal trial have surpassed the three-month follow-up window, marking a key clinical milestone as the study advances toward the primary efficacy endpoint at 12 months.
Analysis · COCH · Industrial Applications And Services
Envoy Medical's Q2 2026 results show a net loss of $7.3 million and cash of $19.7 million, providing runway only through Q1 2027 per the recent 10-Q. The company submitted the first module of its modular PMA application to the FDA and reported positive 12-month data from its pivotal Acclaim cochlear implant trial, with a mean CNC word recognition score of 53.2% versus a 15.2% baseline. These milestones advance the regulatory timeline, but the persistent going concern risk and near-term cash needs remain critical. The termination of the ATM facility removes a potential overhang but also eliminates a source of capital.
At the time of this filing, COCH was trading at $0.71 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $54.2M. The 52-week trading range was $0.36 to $1.89. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.